Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

Core Viewpoint - Neuphoria Therapeutics Inc. urges shareholders to vote for its director nominees as recommended by Institutional Shareholders Services (ISS), emphasizing the board's proactive actions and strategic review process to maximize shareholder value [1][2][3]. Company Overview - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders, with its lead drug candidate BNC210 aimed at treating post-traumatic stress disorder (PTSD) [7]. - The company has halted the development of BNC210 for social anxiety disorder following a Phase 3 clinical trial that missed its primary and secondary endpoints [7]. Proxy Contest - ISS has recommended that shareholders vote for Neuphoria's director nominees, Peter Miles Davies and David Wilson, while withholding votes for the dissident nominees from Lynx1 Capital Management [1][3]. - The board's actions in response to the clinical trial results and the dissident's offer have been deemed appropriate, with a commitment to transparency and shareholder updates [6]. Strategic Review - Neuphoria's board is conducting a strategic review to explore alternatives that could provide maximum value to shareholders, which includes inviting the dissident to participate under similar terms as other parties [6]. - The company has raised capital proactively ahead of the Phase 3 trial data readout, strengthening its balance sheet for the ongoing strategic review [6].